🟢 Neurosense Therapeutics is trading 6.44% up in after-hours trading

Neurosense Therapeutics is trading 6.44% up at $0.48 after no new company-specific announcement was identified for August 14, 2026.

• An August 13 CEO letter said financing for the Phase 3 PARAGON ALS study is taking longer than expected; Nasdaq compliance remains an issue.
• The move appears isolated; markets were mixed after the regular session.
• An August 6 Health Canada filing update is older and does not clearly explain the after-hours increase.